The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis

Other Allergic Rhinitis Clinical Trial

Official title:

The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02271620
• Other study ID #: 759/25569(EC3)
• Status: Completed
• Phase: N/A
• First received: September 9, 2014
• Last updated: March 21, 2018
• Start date: January 2014
• Est. completion date: April 2016

Study information

• Verified date: March 2018
• Source: Mahidol University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• To determine prevalence of local allergic rhinitis (LAR)

• To evaluate clinical characteristic and severity of local allergic rhinitis

• To measure changing of tryptase and Specific IgE for Dermatophagoides pteronyssinus (Dp) after nasal allergen provocation test (NAPT)

Description:

Children 8-18 years with NAR were recruited. A NAPT with Der p 1 solutions (NAPT-DP) at 200 AU/mL, 600 AU/mL and 2000 AU/mL at 15-minute interval was performed, respectively. The immediate responses to NAPT-DP were assessed using symptoms score, peak nasal inspiratory flow (PNIF) and acoustic rhinometry (ARM). The nasal tryptase and sIgE-DP were measured at baseline, 15 min and 1 h after positive NAPT-DP. Allergic rhinitis (AR) patients were used as positive control.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: April 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 18 Years

Eligibility

Inclusion Criteria:

• Children 8-15 years who were diagnosed with nonallergic rhinitis (NAR) at least 1 year

• No respiratory infections in the previous 4 weeks

• No following treatment of

• systemic corticosteroid 4 weeks

• intranasal corticosteroid 2 weeks

• oral antihistamine 1 week

• leukotriene antagonist 1 week

Exclusion Criteria:

• Patients with underlying disease:

• chronic rhinosinusitis and nasal polyp

• immunological disease

• chronic renal disease

• hepatobiliary disease

• cardiovascular disease

• cancer

• Parental withdraw consent

• Patient with uncontrolled asthma, peak expiratory flow rate (PEFR) < 80% of predicted

Related Conditions & MeSH terms

• Other Allergic Rhinitis
• Rhinitis
• Rhinitis, Allergic

Intervention

Procedure:
• nasal allergen provocation test
nasal allergen provocation test

Locations

Country	Name	City	State
Thailand	Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University	Bangkok
Thailand	Division of allergy and immunology, Department of pediatric, Siriraj Hospital	Bangkoknoi	Bangkok

Sponsors (1)

Lead Sponsor	Collaborator
Mahidol University

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	prevalence of local allergic rhinitis (LAR)	positive nasal allergen provocation test with Der p1	1 year